Neutropenia is a major dose-limiting toxicity of chemotherapy. By reducing the incidence and duration of neutropenia, filgrastim enables patients to adhere to their chemotherapy schedules without delays or dose reductions, thereby increasing the efficacy of the treatment. This is particularly crucial in cancers that are highly aggressive or rapidly proliferating.
